Europe’s Most Advanced Weather Satellite Is Now Fully Operational
The first of EUMETSAT’s Meteosat Third Generation (MTG) satellites became fully operational today.
MTG-Imager 1 also receives a new name – Meteosat-12 – to mark the occasion.
The two main instruments on board Meteosat-12, the Flexible Combined Imager (FCI) and the Lightning Imager (LI), play a crucial role in enabling meteorological services to help protect lives and livelihoods by providing high-resolution, accurate data for predicting severe weather events.
Data from Meteosat-12’s instruments are now being disseminated to national meteorological services and others for operational use and are expected to have a significant impact on weather forecasting and understanding of our climate.
“MTG is one of the most innovative and complex meteorological satellite systems ever built,” EUMETSAT Director-General Phil Evans said.
“We have been working with our member states’ meteorological services to ensure they can make the best use of the data, which is essential for one of the main challenges they face - the rapid detection and forecasting of severe weather so that citizenry, civil authorities and first responders receive timely warnings.”
“When the full constellation of MTG is in place, it will be possible, for the first time, to observe the full lifecycle of a convective storm, from before clouds begin to form through to detection of lightning strikes.”
Efficient and impactful use of this new data will also be central to the EU-funded Space for Early Warnings in Africa project, implemented with the African Union Commission. Today, Council approved EUMETSAT’s involvement via an agreement with the European Commission. Starting in January 2025, the project will enhance African capacity to access and process Earth observation data, strengthening early warning systems and resilience to severe weather.
In addition to the FCI and LI, Meteosat-12 also carries the Data Collection and Retransmission Service (DCS) and the Geostationary Search and Rescue Relay (GEOSAR) transponder.
The DCS acquires observations and environmental data from ground-based meteorological platforms in its field of view then transmits them to the MTG ground segment. The GEOSAR transponder acquires signals from distress beacons in its field of view and transmits them to rescue services.
An anomaly in a module of the Flexible Combined Imager meant its commissioning phase lasted longer than anticipated when the spacecraft was launched in mid-December 2022.
“A great deal of hard work, dedication and ingenuity went in to overcoming the anomaly while the satellite was already in orbit 36,000km above the Earth,” Evans said. “I pay tribute to the EUMETSAT teams, supported by ESA and the industry, that achieved that feat and enabled us to reach this important milestone today where we are confident of the quality and reliability of the data we are providing to those who need it.”
Note to editors:
- live imagery from Meteosat-12 is available on the EUMETSAT website: https://www.eumetsat.int/real-time-imagery/earth-view
- Media kit: UNDER EMBARGO UNTIL 04.12.2024 AT 13h15 - METEOSAT 12 becomes operational | Trello
About EUMETSAT
EUMETSAT, Europe’s meteorological satellite agency, monitors the weather and climate from space. Based in Darmstadt, Germany, EUMETSAT provides its 30 member states with meteorological imagery and data that are essential for keeping their communities safe and for the benefit of critical sectors of their economies.
EUMETSAT’s 30 member states are: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.
For more information, see the EUMETSAT website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204449728/en/
Contacts
Media Relations EUMETSAT:
Tel: +49 6151 807 7320
Email: press@eumetsat.int
www.eumetsat.int -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.eumetsat.in
t&esheet=54161656&newsitemid=20241204449728&lan=en-US&anchor=www.eumetsat.int&in
dex=3&md5=b5658ad5621c92013fc6ca7c401f9364
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Avenue Capital Partners Establishes Paris France Office and Xavier Lambert Joins as Head of Europe to Lead Firm’s EU Expansion10.12.2024 08:00:00 CET | Press Release
Pacific Avenue Capital Partners, LLC (“Pacific Avenue”), a Los Angeles-headquartered private equity firm focused on corporate divestitures, carve-outs, and other complex situations in the middle market, announced today the opening of a European office in Paris, France. The office will be led by Xavier Lambert, who joins the firm as Managing Director – Head of Europe. Opening a Paris office underscores Pacific Avenue's continued focus on being a solutions provider to corporate sellers globally. With increasing carve-out and divestiture activity globally, and a growing number of Pacific Avenue’s deals with international operations, establishing a presence in Europe is a natural step in fulfilling the firm’s strategy. The addition of Mr. Lambert will expand the firm’s international footprint and add capabilities to serve global corporate sellers and Pacific Avenue businesses with international operations. "Expanding our footprint in Europe marks a pivotal milestone in Pacific Avenue’s gro
Media Release: Allianz lifts financial ambitions at its Capital Markets Day 202410.12.2024 07:07:00 CET | Press Release
Outperforming on key 2024 financial targets, Allianz has set ambitious financial targets through 2027 at its Capital Markets Day 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209829384/en/ Oliver Bäte, Chief Executive Officer of Allianz SE (Photo: Allianz SE) In a world of uncertainty, Allianz aims to capitalize on its role as a trusted partner of choice by growing its customer base with innovative protection and retirement solutions and seamless services. Allianz will focus on three levers to sustain its strong value creation momentum. First, driving smart growth by winning new customers, increasing cross-sell, and reducing churn. Second, reinforcing productivity through continuous delivery of its productivity agenda, also leveraging latest generative AI solutions. Third, strengthening business and financial resilience, supported by a refined capital management framework. Oliver Bäte, Chief Executive Officer of Al
Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders10.12.2024 05:00:00 CET | Press Release
Sirius Therapeutics today announced promising preliminary data from its Phase 1 first-in-human clinical trial of SRSD107, a next generation siRNA therapeutics under clinical development for the prevention and treatment of thromboembolic disorders, such as myocardial infarction, ischemic stroke, and venous thromboembolism. The trial data were presented during a poster session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, CA. SRSD107 is designed to inhibit Factor XI (FXI), a protein in the coagulation pathway that has shown potential to reduce thrombosis without significantly increasing the risk of bleeding, a major liability of current drugs. “In this trial, SRSD107 was safe and well tolerated, with pharmacokinetic parameters consistent with a typical siRNA product,” said Dr. Patrick Yue, Sirius’ Chief Medical Officer. “We are encouraged by the marked, prolonged reduction in FXI antigen and activity, and increase in clotting, or throm
Mori Memorial Foundation Issues GPCI – 2024 and GPCI – Financial Centers Reports:10.12.2024 04:00:00 CET | Press Release
The Mori Memorial Foundation’s Institute for Urban Strategies, a research body established by Mori Building, Tokyo’s leading urban landscape developer, today released its Global Power City Index (GPCI) 2024 report on the overall strength of the world’s 48 major cities. For the second time, the report additionally includes the 'GPCI–Financial Centers' index. This index reflects the growing importance of measures taken by major cities to enhance their status as international financial centers, capturing changes in their financial and business environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209714811/en/ The 48 major cities evaluated in Mori Memorial Foundation’s GPCI–2024 Report (Graphic: Business Wire) More than 18 months have elapsed since the World Health Organization declared an end to the COVID-19 pandemic in May 2023. With the resurgence of economic activity, mobility and the expansion of international to
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA ® and Novel Pipeline Assets10.12.2024 02:30:00 CET | Press Release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., today announced the presentation of new clinical data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, underscoring its leadership in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) through continued clinical success with BRUKINSA® (zanubrutinib) and promising advancements in its pipeline assets. “The breadth of data we’re presenting at ASH underscores BRUKINSA’s role as a best-in-class treatment for CLL and highlights BeiGene’s leadership in advancing the treatment landscape for B-cell malignancies,” said Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “BRUKINSA shows tremendous promise for patients as a monotherapy and as a backbone for best-in-class combinations. The combination of BRUKINSA and our investigational BCL2 inhibitor, sonrotoclax, demonstrated significant pot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom